CA2699411A1 - Neuroendocrine factors for treatment of degenerative diseases - Google Patents
Neuroendocrine factors for treatment of degenerative diseases Download PDFInfo
- Publication number
- CA2699411A1 CA2699411A1 CA2699411A CA2699411A CA2699411A1 CA 2699411 A1 CA2699411 A1 CA 2699411A1 CA 2699411 A CA2699411 A CA 2699411A CA 2699411 A CA2699411 A CA 2699411A CA 2699411 A1 CA2699411 A1 CA 2699411A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- repellent factor
- treatment
- prevention
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract 4
- 230000000955 neuroendocrine Effects 0.000 title 1
- 230000002940 repellent Effects 0.000 claims abstract 23
- 239000005871 repellent Substances 0.000 claims abstract 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 21
- 238000004519 manufacturing process Methods 0.000 claims abstract 9
- 229920001184 polypeptide Polymers 0.000 claims abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 9
- 101700004678 SLIT3 Proteins 0.000 claims abstract 7
- 102100025490 Slit homolog 1 protein Human genes 0.000 claims abstract 7
- 239000012634 fragment Substances 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 210000000845 cartilage Anatomy 0.000 claims 11
- 230000007547 defect Effects 0.000 claims 11
- 230000002265 prevention Effects 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 9
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims 2
- 102000009065 Netrin-1 Human genes 0.000 claims 2
- 108010074223 Netrin-1 Proteins 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 210000001188 articular cartilage Anatomy 0.000 claims 2
- 210000003321 cartilage cell Anatomy 0.000 claims 2
- 239000007972 injectable composition Substances 0.000 claims 2
- 210000004901 leucine-rich repeat Anatomy 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- JVJUWEFOGFCHKR-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(3,4-dimethylphenyl)cyclopentane-1-carboxylate;hydrochloride Chemical class Cl.C=1C=C(C)C(C)=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 JVJUWEFOGFCHKR-UHFFFAOYSA-N 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 102000016896 DCC Receptor Human genes 0.000 claims 1
- 108010014066 DCC Receptor Proteins 0.000 claims 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010072970 Meniscus injury Diseases 0.000 claims 1
- 102000010803 Netrins Human genes 0.000 claims 1
- 108010063605 Netrins Proteins 0.000 claims 1
- 241001111421 Pannus Species 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 102000014105 Semaphorin Human genes 0.000 claims 1
- 108050003978 Semaphorin Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000018180 degenerative disc disease Diseases 0.000 claims 1
- 102000012803 ephrin Human genes 0.000 claims 1
- 108060002566 ephrin Proteins 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 claims 1
- 210000003041 ligament Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000030428 polyarticular arthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 108700002783 roundabout Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002885 thrombogenetic effect Effects 0.000 claims 1
- 239000003106 tissue adhesive Substances 0.000 claims 1
- 201000006744 villonodular synovitis Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07018131.8 | 2007-09-14 | ||
| EP07018131A EP2036921A1 (en) | 2007-09-14 | 2007-09-14 | Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases |
| EP08006810 | 2008-04-03 | ||
| EP08006810.9 | 2008-04-03 | ||
| PCT/EP2008/007579 WO2009033715A2 (en) | 2007-09-14 | 2008-09-12 | Neuroendocrine factors for treatment of degenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2699411A1 true CA2699411A1 (en) | 2009-03-19 |
Family
ID=40452588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2699411A Abandoned CA2699411A1 (en) | 2007-09-14 | 2008-09-12 | Neuroendocrine factors for treatment of degenerative diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110002972A1 (enExample) |
| EP (1) | EP2212344B1 (enExample) |
| JP (1) | JP2010539123A (enExample) |
| KR (1) | KR20100075493A (enExample) |
| CN (1) | CN101821283A (enExample) |
| AU (1) | AU2008297889A1 (enExample) |
| BR (1) | BRPI0816784A8 (enExample) |
| CA (1) | CA2699411A1 (enExample) |
| MX (1) | MX2010002716A (enExample) |
| NZ (1) | NZ583851A (enExample) |
| RU (1) | RU2496790C2 (enExample) |
| WO (1) | WO2009033715A2 (enExample) |
| ZA (1) | ZA201001644B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1400024B1 (it) * | 2010-05-21 | 2013-05-17 | Uni Politecnica Delle Marche | Uso farmaceutico di semaforine. |
| MX2013007421A (es) * | 2010-12-23 | 2014-02-03 | Sanofi Sa | Proteina de fusion robo1-fc para uso en el tratamiento del hepatocarcinoma. |
| WO2013003899A1 (en) * | 2011-07-04 | 2013-01-10 | Mesoblast, Inc | Methods of treating or preventing rheumatic disease |
| EP3156074B1 (en) * | 2012-06-15 | 2019-06-05 | The Asan Foundation | Composition for preventing or treating fracture or osteoporosis using slit-robo system |
| ES2442242B1 (es) * | 2012-08-09 | 2014-11-25 | Biotechnology Institute, I Mas D, S.L. | Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. |
| CN104119447A (zh) * | 2013-04-26 | 2014-10-29 | 李华顺 | 含有富含亮氨酸重复序列的融合蛋白及其制法和应用 |
| CN104119448A (zh) * | 2013-04-26 | 2014-10-29 | 李华顺 | 含有富含亮氨酸重复序列的融合蛋白及其制法和应用 |
| CN104119446A (zh) * | 2013-04-26 | 2014-10-29 | 李华顺 | 含有富含亮氨酸重复序列的融合蛋白及其制法和应用 |
| CN104119445A (zh) * | 2013-04-26 | 2014-10-29 | 李华顺 | 含有富含亮氨酸重复序列的融合蛋白及其制法和应用 |
| JPWO2015072527A1 (ja) * | 2013-11-13 | 2017-03-16 | 国立大学法人大阪大学 | ネトリン１含有破骨細胞形成抑制剤 |
| FI3116521T3 (fi) | 2014-03-14 | 2024-10-30 | Univ New York State Res Found | Luun kasvun ja luun rappeutumisen neurogeeninen regulaatio |
| US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
| WO2019161136A1 (en) * | 2018-02-14 | 2019-08-22 | Cornell University | Slit and bone growth modulation |
| PH12021552079A1 (en) * | 2019-02-27 | 2022-07-18 | Daewoong Pharmaceutical Co Ltd | Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases |
| EP4028532A1 (en) * | 2019-09-13 | 2022-07-20 | Rutgers, the State University of New Jersey | Aav-compatible laminin-linker polymerization proteins |
| CN110772632B (zh) * | 2019-11-19 | 2023-08-11 | 四川大学华西医院 | 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途 |
| CN110684805B (zh) * | 2019-11-19 | 2023-08-01 | 四川大学华西医院 | 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用 |
| CN110841057B (zh) * | 2019-11-19 | 2023-08-01 | 四川大学华西医院 | 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用 |
| CN110721308B (zh) * | 2019-11-19 | 2023-08-01 | 四川大学华西医院 | 一种用于治疗骨关节炎的药物复方制剂及其制备方法 |
| CN110694051B (zh) * | 2019-11-19 | 2023-08-01 | 四川大学华西医院 | 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用 |
| CN110711244B (zh) * | 2019-11-19 | 2023-08-01 | 四川大学华西医院 | 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用 |
| US20240277861A1 (en) * | 2021-07-26 | 2024-08-22 | Purotech Bio, Inc. | Anti-hepatitis b virus agent targeting host factor lipg |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2700117B1 (fr) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
| JPH1116490A (ja) * | 1997-06-26 | 1999-01-22 | Kyocera Corp | プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板 |
| US20030032057A1 (en) * | 1997-08-26 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO1999023219A1 (en) * | 1997-10-31 | 1999-05-14 | Osiris Therapeutics, Inc. | Human slit polypeptide and polynucleotides encoding same |
| JPH11164690A (ja) * | 1997-12-05 | 1999-06-22 | Asahi Chem Ind Co Ltd | 脊椎動物スリット蛋白質 |
| US20030096955A1 (en) * | 1998-09-01 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2000055321A2 (en) * | 1999-03-17 | 2000-09-21 | Washington University | Vertebrate protein slit, dna sequence encoding it and uses thereof |
| WO2002006315A2 (en) * | 2000-07-18 | 2002-01-24 | Compugen Ltd. | Novel nucleic acid and amino acid sequences |
| WO2002010217A2 (en) * | 2000-08-02 | 2002-02-07 | The Johns Hopkins University | Endothelial cell expression patterns |
| WO2002012346A2 (en) * | 2000-08-10 | 2002-02-14 | Pharmacia Corporation | A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| US20040265808A1 (en) * | 2001-04-05 | 2004-12-30 | Teresa Garcia | Genes involved in osteogenesis, and methods of use |
| US20050014680A1 (en) * | 2003-04-15 | 2005-01-20 | Crabtree Gerald R. | Methods and compositions for enhancing neuron growth and survival |
| US20060025335A1 (en) * | 2004-01-30 | 2006-02-02 | Kinane Thomas B | Netrin compositions and methods of using the same |
| WO2008073441A2 (en) * | 2006-12-11 | 2008-06-19 | University Of Utah Research Foundation | Compositions and methods for treating pathologic angiogenesis and vascular permeability |
-
2008
- 2008-09-12 EP EP08802131.6A patent/EP2212344B1/en active Active
- 2008-09-12 WO PCT/EP2008/007579 patent/WO2009033715A2/en not_active Ceased
- 2008-09-12 CA CA2699411A patent/CA2699411A1/en not_active Abandoned
- 2008-09-12 BR BRPI0816784A patent/BRPI0816784A8/pt not_active IP Right Cessation
- 2008-09-12 RU RU2010114713/10A patent/RU2496790C2/ru not_active IP Right Cessation
- 2008-09-12 US US12/677,830 patent/US20110002972A1/en not_active Abandoned
- 2008-09-12 AU AU2008297889A patent/AU2008297889A1/en not_active Abandoned
- 2008-09-12 KR KR1020107007806A patent/KR20100075493A/ko not_active Withdrawn
- 2008-09-12 JP JP2010524408A patent/JP2010539123A/ja active Pending
- 2008-09-12 CN CN200880111279A patent/CN101821283A/zh active Pending
- 2008-09-12 NZ NZ583851A patent/NZ583851A/en not_active IP Right Cessation
- 2008-09-12 MX MX2010002716A patent/MX2010002716A/es not_active Application Discontinuation
-
2010
- 2010-03-08 ZA ZA2010/01644A patent/ZA201001644B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110002972A1 (en) | 2011-01-06 |
| WO2009033715A3 (en) | 2010-03-18 |
| WO2009033715A2 (en) | 2009-03-19 |
| JP2010539123A (ja) | 2010-12-16 |
| KR20100075493A (ko) | 2010-07-02 |
| EP2212344A2 (en) | 2010-08-04 |
| RU2496790C2 (ru) | 2013-10-27 |
| AU2008297889A1 (en) | 2009-03-19 |
| NZ583851A (en) | 2012-06-29 |
| CN101821283A (zh) | 2010-09-01 |
| EP2212344B1 (en) | 2014-03-26 |
| BRPI0816784A2 (pt) | 2015-03-24 |
| ZA201001644B (en) | 2011-03-30 |
| BRPI0816784A8 (pt) | 2016-01-19 |
| MX2010002716A (es) | 2010-07-05 |
| RU2010114713A (ru) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2699411A1 (en) | Neuroendocrine factors for treatment of degenerative diseases | |
| US10519213B2 (en) | Fusion proteins of collagen-binding domain and parathyroid hormone | |
| Beck et al. | Structure and function of laminin: anatomy of a multidomain glycoprotein | |
| EP0723588B1 (en) | Activin receptors-like kinase (alk), belonging to the tgf receptor family and/or to the bmp receptor family | |
| EP2370463B1 (en) | A stabilized variant of activin iib receptor | |
| US7163920B2 (en) | Peptide with osteogenic activity | |
| US6632790B1 (en) | Laminin 2 and methods for its use | |
| TW200846359A (en) | Variant activin receptor polypeptides and uses thereof | |
| JPH11262395A (ja) | 骨形成ペプチド | |
| US20250345393A1 (en) | Isoform nell-1 peptide | |
| EP2036921A1 (en) | Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases | |
| WO2012094511A2 (en) | Compositions and methods for the treatment of orthopedic disease or injury | |
| JPWO2004078217A1 (ja) | 骨の石灰化促進因子 | |
| JP2006089395A (ja) | コラーゲン遺伝子の遺伝子産物の産生の増加に起因する疾患の予防および／または治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20140912 |